Multiple Myeloma Gets Three New Drugs
Autor: | Alissa Poh |
---|---|
Rok vydání: | 2016 |
Předmět: |
Oncology
medicine.medical_specialty medicine.drug_class Pharmacology Monoclonal antibody Ixazomib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine medicine Elotuzumab Multiple myeloma business.industry SLAMF7 Daratumumab medicine.disease chemistry 030220 oncology & carcinogenesis Monoclonal Proteasome inhibitor business 030215 immunology medicine.drug |
Zdroj: | Cancer Discovery. 6:4-4 |
ISSN: | 2159-8290 2159-8274 |
Popis: | In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively. |
Databáze: | OpenAIRE |
Externí odkaz: |